Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Early Report: SATURN Trial of Maintenance Tarceva Positive for Improvement in Progression-Free Survival
Please Note: While this is Still Excellent Background Info, New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

Well, it happened again that the first word came from the financial community (report here), as we learned today that a large trial testing the value of maintenance tarceva (erlotinib), the oral EGFR inhibitor, provides a significant improvement in progression-free survival (PFS). In the following slide, I show the design for two similar trials that test the value of tarceva after four cycles of first line treatment of advanced NSCLC. ATLAS and SATURN The first, called the ATLAS trial, is for avastin-eligible patients who would typically receive avastin alone as maintenance therapy after initial chemo/avastin. It randomizes patients to maintenance avastin/tarceva vs. avastin alone. We don't have results from that trial yet. The results we have are from the SATURN trial, which asks a similar question but without the avastin: is there a significant delay in progression if patients who haven't progressed after four cycles of platinum-based standard chemotherapy (and no avastin) receive tarceva as a maintenance therapy, compared with an oral placebo?

The answer we received as that yes, there is a significant benefit for PFS among the 889 enrolled patients, but we don't yet know the absolute magnitude of that benefit or whether it's accompanied by an improvement in overall survival (OS). This result isn't surprising to me. I had been following this very timely question of whether we should now standardly offer maintenance therapy to patients who aren't progressing after 4-6 cycles of initial treatment. As I highlighted in a recent prior post, I have been impressed that the limited evidence with both taxotere (docetaxel) and alimta (pemetrexed) is quite convincingly positive for a highly significant improvement in PFS and a nearly statistically significant improvement in OS (nearly three months in both of the chemo trials). Moreover, my impression of the overall data out there for these three agents is that they're quite comparable overall in their efficacy in a broad population, although there are certainly a minority of patients who show stunning benefits from EGFR inhibitors, and the clinical benefit with alimta appears to be limited to patients with non-squamous NSCLC. I would have been surprised if a similar trend hadn't been seen with the third drug that we commonly recognize as being active in previously treated patients with advanced NSCLC. We have yet to learn any details, though next week I'll be attending the largest meeting dedicated to lung cancer this year, in Chicago, so we may see a presentation of this information. With such a large trial, it's possible that the absolute difference in outcomes isn't enough to lead to significant changes in practice, particularly if there is little or no improvement in survival. Thus far, there hasn't been much of a movement toward accepting maintenance chemotherapy after first line treatment yet, and many of the detractors cite the absence of a significant survival benefit as a key reason (I happen to disagree on this point -- see prior post). But the concept of giving patients an oral, generally well-tolerated therapy may be more appealing in the maintenance setting than more standard IV chemotherapy. I'll certainly add more information about this trial when it becomes available. I'll also be interested to learn from people who have been on both standard chemo and tarceva whether they'd be more amenable to an oral strategy like tarceva, whether they'd be perfectly comfortable continuing on chemo, or whether they'd just really welcome a break from treatment after 3-4 months of initial chemo +/- avastin.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on